Immuneering (IMRX) Income from Continuing Operations (2020 - 2026)
Immuneering's (IMRX) quarterly Income from Continuing Operations came in at 32053050.0 in Q1 2026, down 110.46% year-on-year from 306305746.53 in Q1 2025, and down 165.32% quarter-over-quarter from 12080726.0 in Q4 2025.
Immuneering (IMRX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Immuneering's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 32053050.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 110.46% year-over-year to 32053050.0 in Q1 2026; TTM through Mar 2026 was 108670193.0, a 45.18% decrease from a year earlier, with the FY2025 full-year figure at 129714984.0, down 7.67% from the prior year.
- Income from Continuing Operations slipped to 32053050.0 in Q1 2026 per IMRX's latest filing, from 12080726.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 12080726.0 in Q4 2025 and bottomed at 44500816.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 19379811.0 (2022), against an average of 22252255.76.
- Across the five-year window, Income from Continuing Operations tumbled 188.98% in 2022 and surged 40.55% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 13598653.0 in 2022, then fell by 15.75% to 15740444.0 in 2023, then fell by 16.43% to 18326461.0 in 2024, then jumped by 34.08% to 12080726.0 in 2025, then slumped by 165.32% to 32053050.0 in 2026.
- Per Business Quant, the three latest IMRX Income from Continuing Operations figures stand at 32053050.0 (Q1 2026), 12080726.0 (Q4 2025), and 44500816.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Immuneering | 279.33 Mn | 279.33 Mn | - | -32.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.05 Mn |
| Dec 31, 2025 | -12.08 Mn |
| Sep 30, 2025 | -44.50 Mn |
| Jun 30, 2025 | -20.04 Mn |
| Mar 31, 2025 | -15.23 Mn |
| Dec 31, 2024 | -18.33 Mn |
| Sep 30, 2024 | -20.88 Mn |
| Jun 30, 2024 | -20.42 Mn |
| Mar 31, 2024 | -14.71 Mn |
| Dec 31, 2023 | -15.74 Mn |
| Sep 30, 2023 | -25.99 Mn |
| Jun 30, 2023 | -34.34 Mn |
| Mar 31, 2023 | -14.06 Mn |
| Dec 31, 2022 | -13.60 Mn |
| Sep 30, 2022 | -38.85 Mn |
| Jun 30, 2022 | -19.38 Mn |
| Mar 31, 2022 | -18.08 Mn |
| Dec 31, 2021 | -11.00 Mn |
| Sep 30, 2021 | -64.86 Mn |
| Jun 30, 2021 | -19.54 Mn |